CASE STUDY

^{11}C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia

Nicolas Nicastro[1,2] (iD), Ajenthan Surendranathan[1], Elijah Mak[1], James B. Rowe[3,*] & John T. O'Brien[1,*]

[1]Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
[2]Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland
[3]Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Correspondence
John O'Brien, Department of Psychiatry, University of Cambridge School of Clinical Medicine, Box 189, Level E4 Cambridge Biomedical Campus, CB2 0SP Cambridge, United Kingdom. Tel: +44 1223 760 682; Fax: +44 1223 336 968; E-mail: john.obrien@medschl.cam.ac.uk

Abstract

There is evidence of increased microglial activation in Parkinson's disease (PD) as shown by in vivo PET ligand such as ^{11}C-PK11195. In addition, diffusion tensor imaging (DTI) imaging reveals widespread changes in PD, especially when the associated dementia develops. In the present case series, we studied five subjects with Parkinson's disease dementia (PDD). Our findings suggest that while DTI metrics mirror cognitive severity, higher ^{11}C-PK11195 binding seems to be associated with a relative preservation of both white matter tracts and cognition. Longitudinal studies are warranted to tackle the complex relationship between microglial activation and structural abnormalities in neurodegenerative conditions.

Introduction

Neuroinflammation is increasingly recognized as a key contributor to neurodegeneration in Parkinson's disease (PD) and dementia.[1] PET probes have been developed to assess in vivo brain inflammation, for example, by targeting translocator protein (TSPO).[2] Among those, ^{11}C-PK11195 is one of the most widely used ligands to estimate microglial activation.[3] Recent studies in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) have shown that microglial activation, as measured with ^{11}C-PK11195 PET, is more prominent in patients at an earlier disease stage.[4,5] Diffusion tensor imaging (DTI), on the other hand, is an application of diffusion-weighted magnetic resonance imaging designed to assess microstructural integrity based

on motion of water molecules. Impaired white matter integrity in people with PD has been consistently observed in corpus callosum, in relation to cognitive impairment and development of dementia.[6,7] In the present case series, we studied ^{11}C-PK11195 binding as an index of neuroinflammation, and its association with DTI, motor, and cognitive features of Parkinson's disease dementia (PDD).

Subjects and Methods

We studied five PDD subjects who were recruited within the Neuroimaging of Inflammation in Memory and other Disorders (NIMROD) study protocol.[8] Demographics are available in Table 1. Each subject underwent structural MRI, 3T DTI, and ^{11}C-PK11195 PET imaging, as well as

in-depth neuropsychological and motor assessment, including Addenbrooke's Cognitive Evaluation Revised (ACER) and Movement Disorders Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) part III motor assessment.

Mean cortical thickness was obtained with Freesurfer 6.0 using the standard processing pipeline described in.[9] DTI imaging was processed with FSL 6.0.[10] Briefly, this included registration of all diffusion-weighted images to the $b = 0$ (i.e., no diffusion) volume using the FMRIB Software Library (FSL) Diffusion Toolbox, followed by brain masks creation with *Brain Extraction Tool*, head movement, and eddy currents correction. We then used *DTIfit* to independently fit the diffusion tensor for each voxel, resulting in the derivation of fractional anisotropy (FA), mean and radial diffusivity (MD and RD, respectively).

Details about ^{11}C-PK11195 PET processing are available in[4]. In brief, binding in each region of interest was quantified using non-displaceable binding potential (BP_{ND}) determined with a simplified reference tissue model incorporating vascular binding correction and reference region time-activity curve estimation from supervised cluster analysis using four kinetic classes. Regional BP_{ND} was corrected for CSF contamination through division of the region of interest time-activity curve with the mean region of interest fraction of grey and white matter. Regional BP_{ND} binding was obtained for each subject with the Hammers atlas.[4,11]

Subsequently, regional ^{11}C-PK11195 binding Z-scores were computed by comparing each PDD subject's values to 16 similarly aged control subjects (mean ± SD age 69.7 ± 6.6 years, 50% female participants, ACER score 92.5 ± 5.6) scanned with the same imaging protocol,[2] with Z-scores higher/lower than 2.0 considered as significant. Spearman correlations and regression analyses were performed in the PDD group between composite lobar

Table 1. Demographics, clinical, and imaging features of included PDD subjects.

| Subject	Age (years), Gender	MDS-UPDRS III, *ON-state*	ACER	DTI global radial diffusivity	Significant ^{11}C-PK11195 BP_{ND} changes compared to Controls
PDD 1	78, M	36	86	5.11×10^{-4}	Putamen (↑), substantia nigra (↓)
PDD 2	70, M	40	80	5.36×10^{-4}	Parahippocampal gyrus (↓)
PDD 3	70, M	48	76	6.19×10^{-4}	Substantia nigra (↓)
PDD 4	81, M	36	69	6.09×10^{-4}	Midbrain (↓), medulla (↓)
PDD 5	68, M	34	85	4.83×10^{-4}	Mesial anterior temporal lobe (↓), fusiform gyrus (↓), superior parietal gyrus (↓), lateral orbital gyrus (↓), amygdala (↓), nucleus accumbens (↓), substantia nigra (↓), pons (↓)
Mean ± SD	73.4 ± 5.7	38.8 ± 5.6	79.2 ± 7.0	5.52×10^{-4}	

Figure 1. Axial ^{11}C-PK11195 BP_{ND} images and T1-weighted structural MRI of the five PDD included in the study and one representative control subject (65-year-old female participant, ACER 96/100). PDD patients have similar ^{11}C-PK11195 binding than the control participants, except PDD 5 who has lower binding values in several regions (cf. Table 1).

(frontal, temporal, parietal, occipital) and whole-cortex ^{11}C-PK11195 BP$_{ND}$, DTI metrics, and clinical data. Given the exploratory design of the study, results were not corrected for multiple comparisons.

Results

Demographics and main findings are available in Table 1. The analyses revealed that PDD subjects had comparable or lower levels of whole-cortex as well as regional ^{11}C-PK11195 binding relative to controls (Fig. 1). In addition, lobar occipital ^{11}C-PK11195 binding was inversely correlated with MD and RD after adjusting for mean cortical thickness (*linear regression*, for MD: $B = -415.6$, $P = 0.035$, adjusted $R^2 = 0.89$; for RD: B coefficient $= -348.6$, $P = 0.032$, adjusted $R^2 = 0.90$), that is, higher ^{11}C-PK11195 was associated with a relative preservation of white matter integrity. The directionality of these PET-MRI correlations was congruent with those from neuropsychological data. In fact, ACER score positively correlated with frontal ^{11}C-PK11195 binding when adjusting for mean cortical thickness (*linear regression*, $B = 641.2$, $P = 0.014$, adjusted $R^2 = 0.95$). In addition, there was a trend for higher ACER scores being related to preserved DTI metrics (lower MD/RD and higher FA, Spearman $P = 0.10$, rho $= -0.80$ for MD/RD and 0.80 for FA). There was no significant association between MDS-UPDRS part III score and ^{11}C-PK11195 binding or DTI metrics.

Discussion

Our study suggests that higher ^{11}C-PK11195 binding is associated with a relative preservation of both white matter tracts and cognition. Specifically, we found that DTI metrics mirror disease severity, and that PDD subjects had similar or reduced ^{11}C-PK11195 binding compared to controls.[6,12] While these findings require confirmation with larger samples, longitudinal data, and finer imaging proxies (e.g., voxel-wise DTI association with ^{11}C-PK11195 binding), this case series brings novel evidence for an early role of neuroinflammation in the pathophysiology of PDD and confers additional support for the hypothesis that central inflammation represents a potential therapeutic target in dementia.

Acknowledgments

Author Contributions

Nicolas Nicastro contributed to research project execution, data review and critique, and manuscript draft. Ajenthan Surendranathan also contributed to research project execution, data review, and manuscript review. Elijah Mak contributed to research project execution, data review, and manuscript review. James B. Rowe contributed to research project conception, organization and execution, data review, and manuscript review. John T. O'Brien contributed to research project conception, organization and execution, data review, and manuscript review.

Conflict of Interest

The authors have no conflict of interest to report.

References

1. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013;38:938–949.

2. Stefaniak J, O'Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry 2016;87:21–28.

3. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461–467.

4. Surendranathan A, Su L, Mak E, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 2018;141:3415–3427.

5. Femminella GD, Dani M, Wood M, et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology 2019;92:e1331–e1343.

6. Minett T, Su L, Mak E, et al. Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. J Neurol 2018;265:1528–1539.

7. Kamagata K, Tomiyama H, Motoi Y, et al. Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: comparison with conventional diffusion tensor imaging. Magn Reson Imaging 2013;31:1501–1506.

8. Bevan-Jones WR, Surendranathan A, Passamonti L, et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of

brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 2017;7: e013187.

9. Fischl B. FreeSurfer. Neuroimage 2012;62:774–781.

10. Jenkinson M, Beckmann CF, Behrens TE, et al. Fsl. Neuroimage 2012;62:782–790.

11. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003;19: 224–247.

12. Varnas K, Cselenyi Z, Jucaite A, et al. PET imaging of [(11)C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging 2019;46:367–375.